IMA ImageneBio Inc Total Debt to Capital

IMA (ikenaoncology.com) - company brandmark

This daily price chart for ImageneBio Inc (IMA) on the GURU.Markets platform reflects the 0.03 metric. ImageneBio Inc minimizes capital expenditures by outsourcing oncology drug trials to third-party contractors. A stock option system ensures the stability of the scientific staff, while current hiring focuses on drug delivery experts. However, the lack of consistent profit and fierce sector competition force the business to rely on new equity issuances.

IMA Ikena Oncology, Inc. All Debt to Shareholders' Equity Ratio (07/29/2025 - 10/28/2026)

Analytical breakdowns for ImageneBio Inc

- price and consensus price forecast:
Stock Price ImageneBio|IMA - Fair Value Consensus
- market capitalization data:
Market Capitalization Ikena Oncology|IMA - Enterprise Value
- book capitalization data:
Net Assets per Single Share Ikena Oncology|IMA - Accounting Value of Company|Market Value to Book Value Ratio ikenaoncology.com|IMA - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital ImageneBio Inc|IMA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio ImageneBio|IMA - Aggregate Debt Obligations|Debts to Book Capitalization Ikena Oncology|IMA - Long-Term Debt Volume|Company Short-Term Debt Ikena Oncology
Basic company analysis:ImageneBio Inc - IMA
Finished products of Ikena Oncology, Inc.

For a long-term investor, the reliability of ImageneBio Inc (IMA) is determined by the balance between cancer therapy development costs and the sources used to cover them. This ratio measures the proportion of debt obligations within the equity structure, and analyzing the shift in the debt-to-equity ratio allows for an assessment of the biotech's risk of dependence on external borrowing while seeking strategic partners.

Key competitors

ARGX - Total Debt to Capital|All Debt to Shareholders' Equity Ratio BioNTech Inc.|Total Debt to Capital ABVX|Total Debt to Capital ADMA (ADMA Corp)|Debt to Equity Protagonist Therapeutics|immunovant.com - All Debt to Shareholders' Equity Ratio|KNSA: Debt to Equity|GRFS - Total Debt to Equity Ratio|ADPT: Total Debt to Capital|Total Debt to Capital Celldex Corp|AUPH - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio biocryst.com|VERA (Vera Therapeutics) - Total Debt to Capital|Total Debt to Capital Coefficient DNTH (Dianthus Therapeutics Inc)|Pharvaris Corp - Debt to Equity|AbCellera - Total Debt to Equity Ratio|TRML: Debt to Equity|precigen.com (PGEN) - Total Debt to Equity Ratio|PHAR: Total Debt to Equity Ratio|NKTR (Nektar Therapeutics Inc) - Total Debt to Capital|Debt to Equity Upstream Bio Corp (UPB)|Debt to Equity Ratio Zenas Corp|Immunome, Inc. - Total Debt to Capital|Debt to Capital gossamerbio.com (GOSS)|Total Debt to Capital KALV|Septerna, Inc. - Total Debt to Capital Coefficient|PVLA: Debt to Equity|SVRA - Total Debt to Equity Ratio|RIGL: Total Debt to Capital|anaptysbio.com (ANAB) - Total Debt to Capital|Astria Therapeutics, Inc. - Total Debt to Capital|Debt to Capital Ratio enGene Holdings Inc|RAPT Therapeutics, Inc. - Total Debt to Capital|Debt to Capital JBIO (aerovatetx.com)|ACRS - Debt to Equity|Debt to Equity Ratio kyvernatx.com KYTX|TLSA (Tiziana Life Sciences Ltd) - Total Debt to Capital|CABA - Debt to Capital|Ventyx Bio (VTYX) - Total Debt to Capital|Theratechnologies, Inc (THTX) - Debt to Equity|AVTX: Total Debt to Capital|Total Debt to Capital Coefficient ELDN|Agenus Inc. - Debt to Equity|Debt to Capital Climb Bio Inc. CLYM|Total Debt to Equity Ratio Zura Bio Limited|All Debt to Shareholders' Equity Ratio aTyr Pharmaceuticals ATYR|Total Debt to Capital ADAG (Adagene Corp)|STTK: Total Debt to Capital Coefficient|Debt to Equity equilliumbio.com|Connect Biopharma Holdings Limited (CNTB) - Debt to Equity Ratio|Total Debt to Capital IMUX|Total Debt to Equity Ratio Atara Biotherapeutics Inc|IFRX (InflaRx N.V.) - Total Debt to Capital|Total Debt to Capital Coefficient XFOR (x4pharma.com)|Adicet Bio, Inc. - Debt to Equity|Total Debt to Equity Ratio Celularity Inc CELU|INmune Bio Corp - Total Debt to Capital|BRNS: Total Debt to Capital|Debt to Equity Kezar Life Sciences (KZR)|sabbiotherapeutics.com (SABS) - Aggregate Debt to Equity|AKTX - Total Debt to Capital|All Debt to Shareholders' Equity Ratio Enlivex Therapeutics, Ltd.|Total Debt to Capital QTTB|Total Debt to Capital GOVX (GeoVax Corp)|Debt to Equity Edesa Biotech, Inc.|ibioinc.com - All Debt to Shareholders' Equity Ratio|CARM: Debt to Equity|XTLB - Total Debt to Equity Ratio|BOLT: Total Debt to Capital|Total Debt to Capital HCW Biologics|APVO - Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio AIM ImmunoTech, Inc.|ADTX (Aditxt) - Total Debt to Capital|Total Debt to Capital Coefficient GRI (GRI Bio Inc)|XORTX - Debt to Equity|Vyome Therapeutics - Total Debt to Equity Ratio|REVB: Debt to Equity|indaptusrx.com (INDP) - Total Debt to Equity Ratio|SCNI: Total Debt to Equity Ratio|CALI (CalciMedica) - Total Debt to Capital|Debt to Equity Affimed NV (AFMD)|Debt to Equity Ratio Allakos Therapeutics|HOOKIPA Pharma Inc. - Total Debt to Capital|Debt to Capital igmbio.com (IGMS)|Total Debt to Capital ITOS|Ocean Biomedical Inc - Total Debt to Capital Coefficient|TCBP: Debt to Equity|THRD - Total Debt to Equity Ratio